Citations Report
Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report
Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.
Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
105 | 141 | 28 | 8 | 28 |
Year wise citations received |
543 | 553 | 590 | 563 | 587 |
| Journal total citations count | 6601 |
| Journal Impact Factor | 6.49 |
| Journal 5 years Impact Factor | 12.17 |
| Journal CiteScore | 11.19 |
| Journal h-index | 41 |
| Journal h-index since 2016 | 26 |
Ohlsen, Ruth, and Fiona Gaughran. "Schizophrenia: A major risk factor for cardiovascular disease." British Journal of Cardiac Nursing 6, no. 5 (2011): 228-232. |
|
Aquila, Ralph, and Leslie Citrome. "Cognitive impairment in schizophrenia: the great unmet need." CNS spectrums 20, no. S1 (2015): 32-40. |
|
Watson, Christopher Mark, Aneeka Alexander, and Alexander Panickacheril John. "The role of C-reactive protein in early detection of myocarditis associated with clozapine." Journal of clinical psychopharmacology 38, no. 5 (2018): 540-542. |
|
Strassnig, Martin, Jennifer Clarke, Steve Mann, Gary Remington, and Rohan Ganguli. "Body composition, pre?diabetes and cardiovascular disease risk in early schizophrenia." Early intervention in psychiatry 11, no. 3 (2017): 229-236. |
|
Kantrowitz, Joshua T. "Managing negative symptoms of schizophrenia: how far have we come?." CNS drugs 31, no. 5 (2017): 373-388. |
|
Möller, Marisa, Jan L. Du Preez, Robin Emsley, and Brian H. Harvey. "Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment." Neuropharmacology 62, no. 8 (2012): 2499-2506. |
|
Hsu, Jer-Hwa, I-Chia Chien, Ching-Heng Lin, Yiing-Jenq Chou, and Pesus Chou. "Hyperlipidemia in patients with schizophrenia: a national population-based study." General hospital psychiatry 34, no. 4 (2012): 360-367. |
|
Weston-Green, Katrina, Xu-Feng Huang, and Chao Deng. "Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor." CNS drugs 27, no. 12 (2013): 1069-1080. |
|
Miola, Alessandro, Veronica Dal Porto, Tal Tadmor, Giovanni Croatto, Paolo Scocco, Mirko Manchia, Andre F. Carvalho et al. "Increased C?reactive protein concentration and suicidal behavior in people with psychiatric disorders: A systematic review and meta?analysis." Acta Psychiatrica Scandinavica (2021). |
|
Laursen, Thomas M., Betina B. Trabjerg, Ole Mors, Anders D. Børglum, David M. Hougaard, Manuel Mattheisen, Sandra M. Meier et al. "Association of the polygenic risk score for schizophrenia with mortality and suicidal behavior-A Danish population-based study." Schizophrenia research 184 (2017): 122-127. |
|
Peleg-Raibstein, Daria, Joram Feldon, and Urs Meyer. "Behavioral animal models of antipsychotic drug actions." Current Antipsychotics (2012): 361-406. |
|
Chien, I-Chia, Ching-Heng Lin, Yiing-Jenq Chou, and Pesus Chou. "Risk of hypertension in patients with bipolar disorder in Taiwan: a population-based study." Comprehensive psychiatry 54, no. 6 (2013): 687-693. |
|
Knott, Verner J., Anne M. Millar, Judy F. McIntosh, Dhrasti K. Shah, Derek J. Fisher, Crystal M. Blais, Vadim Ilivitsky, and Ed Horn. "Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention." Biological psychology 88, no. 1 (2011): 83-93. |
|
Sarlon, Emmanuelle, Dirk Heider, Aurélie Millier, Jean-Michel Azorin, Hans-Helmut König, Karina Hansen, Matthias C. Angermeyer, Samuel Aballéa, and Mondher Toumi. "A prospective study of health care resource utilisation and selected costs of schizophrenia in France." BMC health services research 12, no. 1 (2012): 1-8. |
|
Severance, Emily G., and Robert H. Yolken. "Tracking a dysregulated gut-brain axis with biomarkers of the microbiome." Biomarkers in Neuropsychiatry 2 (2020): 100009. |
|
Rook, Jerri M., Masahito Abe, Hyekyung P. Cho, Kellie D. Nance, Vincent B. Luscombe, Jeffrey J. Adams, Jonathan W. Dickerson et al. "Diverse effects on M1 signaling and adverse effect liability within a series of M1 Ago-PAMs." ACS chemical neuroscience 8, no. 4 (2017): 866-883. |
|
Fitzgerald, Paul J. "Is elevated norepinephrine an etiological factor in some cases of schizophrenia?." Psychiatry research 215, no. 3 (2014): 497-504. |
|
Morrens, Manuel, Livia De Picker, Jarl K. Kampen, and Violette Coppens. "Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis." Schizophrenia Research (2020). |
|
Martins-de-Souza, Daniel, Murtada Alsaif, Agnes Ernst, Laura W. Harris, Nancy Aerts, Ilse Lenaerts, Pieter J. Peeters et al. "The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia." BMC research notes 5, no. 1 (2012): 1-8. |
|
de Kuijper, Gerda, Hans Mulder, Heleen Evenhuis, Frans Scholte, Frank Visser, and Pieter J. Hoekstra. "Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics." Research in developmental disabilities 34, no. 9 (2013): 2799-2809. |
|